Polycythemia vera (pol-e-sy-THEE-me-uh VEER-uh) is a slow-growing blood cancer in which your bone marrow makes too many red blood cells. These excess cells thicken your blood, slowing its flow. They also cause complications, such as blood clots, which can lead to a heart attack or stroke.
Polycythemia vera isn't common. It usually develops slowly, and you might have it for years without knowing. Often the condition is found during a blood test done for another reason.
Without treatment, polycythemia vera can be life-threatening. But proper medical care can help ease signs, symptoms and complications of this disease. Over time, in some cases there's a risk of progressing to more-serious blood cancers, such as myelofibrosis or acute leukemia.
Feb. 08, 2017
- Tefferi A. Diagnostic approach to the patient with polycythemia. http://www.uptodate.com/home. Accessed Nov. 16, 2016.
- Polycythemia vera. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/poly/. Accessed Nov. 16, 2016.
- Tefferi A. Prognosis and treatment of polycythemia vera. http://www.uptodate.com/home. Accessed Nov. 16, 2016.
- Polycythemia vera facts. Leukemia & Lymphoma Society. https://www.lls.org/llssearch?search-terms=polycythemia+vera&search_language=en. Accessed Nov. 16, 2016.
- Mesa RA, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2013;31:1285.
- Brian JC, et al. Overcoming treatment challenges in myelofibrosis and polycythemia vera: The role of ruxolitinib. Cancer Chemotherapy and Pharmacology. 2016;77:1125.
- Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease. Journal of Clinical Oncology. 2016;34:151.
- Polycythemia vera. Merck Manual Professional Version. http://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/polycythemia-vera. Accessed Nov. 16, 2016.